1 |
VITALI C, BOMBARDIERI S, JONSSON R, et al. Classification criteria for sjogren's syndrome: a revised version of the European criteria proposed by the American European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6):554-558.
|
2 |
CHISHOLM D M, MASON D K. Labial salivary gland biopsy in Sjögren's disease[J]. J Clin Pathol,1968,21 (5): 656-660.
|
3 |
RADENSKA-LOPOVOK S G, KARANOVA M S, ZANOZIN A S, et al. Evaluation of morphological activity of primary Sjogren's syndrome on bioptates of minor salivary glands[J]. Arkh Patol, 2023,85(1):5-9.
|
4 |
LONGOBARDI S, LOPEZ-DAVIS C, KHATRI B,et al. Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B[J]. Ann Rheum Dis, 2023,82(9):1181-1190.
|
5 |
中国医师协会风湿免疫科医师分会干燥综合征学组.原发性干燥综合征诊疗规范[J]. 中华内科杂志,2020,59(4): 269-276.
|
6 |
FLORES-CHÁVEZ A, KOSTOV B, SOLANS R, et al. Severe,life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)[J]. Clin Exp Rheumatol, 2018, 112(3):121-129.
|
7 |
李慧敏,余陈欢,黄燕静,等. 400例干燥综合征患者临床并发症的特点分析[J]. 国际流行病学传染病学杂志,2019,46(3):247-250.
|
8 |
LIAMPAS A, PARPERIS K, EROTOCRITOU M F, al et, Primary Sjögren syndrome-related peripheral neuropathy: A systematic review and meta-analysis[J]. Eur J Neurol, 2023,30(1):255-265.
|
9 |
AFZALI A M, MOOG P, KALLURI S R, et al. CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype[J]. Front Neurol, 2023,14:1128315.
|
10 |
BERARDICUTI O, MARINO A, GENOVALI I, et al. Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis[J]. J Clin Med,2023,12(7):2586.
|
11 |
VIRDEE S, GREENAN-BARRETT J, CIURTIN C. A systematic review of primary Sjögren's syndrome in male and paediatric populations[J]. Clin Rheumatol, 2017,36(10):2225-2236.
|
12 |
宣磊,王景,董振华. 65例男性干燥综合征患者的临床特点分析[J]. 医学研究杂志,2017,46(12):137-140.
|
13 |
罗静,陈嘉琪,张丽宁,等. 不同性别和年龄起病原发性干燥综合征患者临床特点比较[J]. 中华风湿病学杂志,2021,25(12):793-799.
|
14 |
陈志锋,田静,欧阳若芸. 原发性干燥综合征合并肺动脉高压的临床特征和危险因素[J]. 中南大学学报(医学版), 2023, 48(3): 339-346.
|
15 |
GOULES A V, ARGYROPOULOU O D, PEZOULAS V C, et al. Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development[J]. Front Immunol, 2020,11: 594096.
|
16 |
ZHANG Y, QIAO L, ZHANG L, Renal tubular acidosis and associated factors in patients with primary Sjögren's syndrome: a registry-based study[J]. Clin Rheumatol, 2023,42(2):431-441.
|
17 |
CHATTERJEE R, BALAKRISHNAN A, KHARBANDA R, et al.Renal involvement in Sjőgren's syndrome: predictors and impact on patient outcomes[J]. Rheumatol Int, 2023,43(7):1297-1306.
|
18 |
GONG Y, LIU H, LI G, et al.Childhood-onset primary Sjögren's syndrome in a tertiary center in China: clinical features and outcome[J]. Pediatr Rheumatol Online J, 2023,21(1):11.
|
19 |
LIN J C, PAN K L, LI C F, et al. Altered subgroups of regulatory T cells in patients with primary Sjögren's syndrome[J]. Heliyon, 2023,9(5):e15565.
|
20 |
CHETT G, DAYER J M, MANGER B, et al. Interleukin-1 function and role in rheumatic disease[J]. Nat Rev Rheumatol, 2016, 12 (1) :14-24.
|
21 |
ÖZCAKA Ö, ALPÖZ E, NALBANTSOY A, al et, Clinical periodontal status and inflammatory cytokines in primary Sjögren's syndrome and rheumatoid arthritis [J]. J Periodontol, 2018,89(8):959-965.
|
22 |
ZHANG S, QU J, WANG L, al et, Activation of Toll-Like Receptor 7 Signaling Pathway in Primary Sjögren's Syndrome-Associated Thrombocytopenia[J]. Front Immunol, 2021,12:637659.
|
23 |
AKIYAMA M, SASAKI T, KANEKO Y, al et, Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG 4 -related disease and primary Sjögren's syndrome adults from a defined population[J]. Clin Exp Rheumatol, 2018, 112(3):157-164.
|
24 |
房星星,路臻豪,汤建平,等. MSCs通过促分泌TGF-β1、IL-6和IL-10抑制干燥综合征患者CD4+ T细胞的活化增殖[J]. 同济大学学报(医学版),2016,37(4):31-35.
|
25 |
CHEN C, LIANG Y, ZHANG Z, al et, Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome[J]. Int Immunopharmacol, 2020,88:106878.
|